An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study - Concepedia

Concepedia

Publication | Closed Access

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study

153

Citations

22

References

2022

Year

Emma Guttman‐Yassky, Eric L. Simpson, Kristian Reich, Kenji Kabashima, Ken Igawa, Tetsuya Suzuki, Hirotaka Mano, Takeshi Matsui, Ehsanollah Esfandiari, Masutaka Furue

Atopic DermatitisModerate-to-severe Atopic DermatitisImmunologyPlacebo-controlled Phase 2BClinical DermatologyAutoimmunityDermatologyImmunotherapyMedicineAnti-ox40 Antibody

References

	Year	Citations

Page 1

Page 1